Company Overview and News
Insulet Corporation (PODD - Free Report) achieves a new milestone in Europe with its Omnipod Insulin Management System. The company announced that this system can now be used together with Novo Nordisk’s (NVO) Fiasp or Fast-Acting Insulin Aspart in Europe.
MASI LMT AMED ISRG UTX PODD
On Sep 18, we issued an updated research report on Insulet Corporation (PODD - Free Report) . We are upbeat about the company's series of developments with respect to expansion of Omnipod's market reach while a tough competitive landscape raises concerns. The stock carries a Zacks Rank #3 (Hold).
MASI AMED ISRG PODD
2018-09-14 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Chicago, IL – August 17, 2018 - Stocks in this week’s article are Entercom Communications Corp. (ETM - Free Report) , Insulet Corp. (PODD - Free Report) , ESCO Technologies Inc. (ESE - Free Report) and Tristate Capital Holdings, Inc. (TSC - Free Report) .
HD ESE ETM.WI PODD FCCTO BGSF ETM FCCTP FCCO HEAR OXY FIVE TSC FCCT
Take a company’s revenues over a given period of time, subtract the cost of production and you will have its earnings! Right from the top brass to research analysts, earnings growth interests every single one. This is because upbeat earnings serve as an indicator of a company’s profitability. It also more often than not leads to an uptick in the share price.
ESE ETM.WI PODD TSC ETM
Insulet Corporation (PODD - Free Report) incurred net loss per share of 3 cents in second-quarter 2018 compared with net loss of 13 cents in the prior-year quarter. Further, the figure in the reported quarter was narrower than the Zacks Consensus Estimate of a loss of 13 cents.
ALGN AMT ISRG CHE PODD GTLS
Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter of 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded.
Insulet (PODD - Free Report) just came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.
CRS CNX.WI CNQ PNK PODD
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-07-30 zacks - 1
Hill-Rom Holdings, Inc. (HRC - Free Report) reported third-quarter fiscal 2018 adjusted earnings per share (EPS) of $1.15, reflecting a 26.4% increase from the year-ago quarter. Adjusted earnings surpassed the Zacks Consensus Estimate by 1.8% and were well above the company’s projected range of $1.12-$1.14.
AMED HRC PODD
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) reported second-quarter 2018 adjusted earnings per share of $1.92, down 7.7% year over year and ahead of the Zacks Consensus Estimate of $1.88.
RSG AMED ZBH PODD
2018-07-27 zacks - 2
GNC Holdings, Inc. (GNC - Free Report) reported second-quarter 2018 adjusted earnings per share (EPS) of 20 cents, reflecting a 52.4% year-over-year plunge. Adjusted EPS however, surpassed the Zacks Consensus Estimate by 42.9%. A significant year-over-year decline in revenues along with escalating costs impedes the bottom-line growth in the reported quarter.
RAD GNC AMED PODD
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET